Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Breast01: saruparib + camizestrant versus physician's choice CDK4/6 inhibitor-based first-line therapy in BRCA1/2 or PALB2-mutated HR-positive HER2-negative advanced breast cancer
MOH_2024-10-30_013698Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of saruparib and camizestrant in breast cancer (3 arms), sponsored by AstraZeneca. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
saruparibcamizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2024-10-30_013698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-10-30_013698.